Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.969 EUR | +0.62% | -7.50% | -10.39% |
Apr. 25 | Transcript : Oriola Oyj, Q1 2024 Earnings Call, Apr 25, 2024 | |
Apr. 25 | Oriola Oyj Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company shows low valuation levels, with an enterprise value at 0.08 times its sales.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
- Sales forecast by analysts have been recently revised upwards.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.39% | 193M | B- | ||
+17.35% | 71.39B | C+ | ||
+2.39% | 25.1B | C+ | ||
-1.22% | 8.59B | C | ||
+6.69% | 8.19B | B | ||
-20.96% | 7.91B | B- | ||
0.00% | 4.54B | B- | ||
+17.12% | 4.31B | B+ | ||
-2.61% | 3.86B | B | ||
+22.08% | 3.64B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- OKDBV Stock
- Ratings Oriola Oyj